全文获取类型
收费全文 | 182篇 |
免费 | 25篇 |
国内免费 | 5篇 |
专业分类
耳鼻咽喉 | 1篇 |
儿科学 | 13篇 |
妇产科学 | 5篇 |
基础医学 | 28篇 |
口腔科学 | 10篇 |
临床医学 | 23篇 |
内科学 | 35篇 |
皮肤病学 | 3篇 |
神经病学 | 8篇 |
特种医学 | 26篇 |
外科学 | 7篇 |
综合类 | 29篇 |
预防医学 | 7篇 |
眼科学 | 1篇 |
药学 | 4篇 |
肿瘤学 | 12篇 |
出版年
2023年 | 1篇 |
2022年 | 3篇 |
2021年 | 7篇 |
2019年 | 1篇 |
2018年 | 4篇 |
2017年 | 1篇 |
2016年 | 2篇 |
2015年 | 3篇 |
2014年 | 8篇 |
2013年 | 6篇 |
2012年 | 6篇 |
2011年 | 4篇 |
2010年 | 6篇 |
2009年 | 8篇 |
2008年 | 7篇 |
2007年 | 9篇 |
2006年 | 5篇 |
2005年 | 3篇 |
2004年 | 3篇 |
2003年 | 2篇 |
2002年 | 3篇 |
2001年 | 2篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1998年 | 17篇 |
1997年 | 14篇 |
1996年 | 13篇 |
1995年 | 8篇 |
1994年 | 9篇 |
1993年 | 7篇 |
1992年 | 1篇 |
1991年 | 1篇 |
1990年 | 3篇 |
1989年 | 2篇 |
1988年 | 8篇 |
1987年 | 3篇 |
1986年 | 6篇 |
1985年 | 1篇 |
1984年 | 2篇 |
1983年 | 4篇 |
1982年 | 1篇 |
1981年 | 4篇 |
1978年 | 1篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 3篇 |
1974年 | 1篇 |
排序方式: 共有212条查询结果,搜索用时 31 毫秒
81.
82.
Meegdes Marissa Ibragimova Khava I. E. Lobbezoo Dorien J. A. Vriens Ingeborg J. H. Kooreman Loes F. S. Erdkamp Frans L. G. Dercksen M. Wouter Vriens Birgit E. P. J. Aaldering Kirsten N. A. Pepels Manon J. A. E. van de Winkel Linda M. H. Tol Jolien Heijns Joan B. van de Wouw Agnes J. Peters Natascha A. J. B. Hochstenbach-Waelen Ananda Smidt Marjolein L. Geurts Sandra M. E. Tjan-Heijnen Vivianne C. G. 《Breast cancer research and treatment》2022,192(2):331-342
Breast Cancer Research and Treatment - The hormone receptor (HR) and human epidermal growth factor receptor 2 (HER2) are the main parameters in guiding systemic treatment choices in breast cancer,... 相似文献
83.
84.
K Reetz C Gaser C Klein J Hagenah C Büchel S Gottschalk PP Pramstaller HR Siebner F Binkofski 《Movement disorders》2009,24(1):99-103
A bilateral compensatory increase of basal ganglia (BG) gray matter value (GMV) was recently demonstrated in asymptomatic Parkin mutation carriers, who likely have an increased risk to develop Parkinson's disease (PD). We hypothesized BG morphological changes in symptomatic Parkin mutation carriers (sPARKIN-MC) and idiopathic PD patients (iPD) after the occurrence of PD symptoms, reflecting the breakdown of compensatory mechanisms. Nine sPARKIN-MC, 14 iPD, and 24 controls were studied clinically and with voxel-based morphometry. Analysis of variance revealed mainly BG decrease of GMV in sPARKIN-MC and to a lesser extent in iPD. However, a slight increase in GMV was also found in the right globus pallidus externus in sPARKIN-MC and in the right putamen in iPD. This may reflect a structural correlate of functional compensation that can only partially be maintained when nigrostriatal neurodegeneration becomes manifest. Simple regression analyses with the UPDRS-III and disease duration score revealed a distinct more bilateral linear decrease of BG GMV in sPARKIN-MC than in iPD that may correspond to previous findings showing a symmetric reduction in putaminal (18)F-DOPA-uptake and bilateral manifestation of symptoms in sPARKIN-MC. In symptomatic PD, BG are subject to a progressive atrophy, which gradually increases with disease severity and duration. 相似文献
85.
86.
87.
88.
89.
MS Rein KV Jackson DB Sable PP Thomas MD Hornstein 《Human reproduction (Oxford, England)》1996,11(2):254-255
The purpose of the present study was to determine whether adrenalandrogen suppression with dexamethasone (DEX) during ovulationinduction improves the outcome of in-vitro fertilization (IVF)cycles. A total of 25 patients with serum dehydroepiandrosteronesulphate (DHEAS) concentrations>2.5 µg/ml were randomizedto receive either 0.5 mg DEX daily or placebo during ovulationinduction with leuprolide acetate down-regulation plus humanmenopausal gonadotrophins (HMG). Nine patients undergoing asubsequent IVF cycle were crossed over to the other treatmentgroup. Ovarian responsiveness and IVF outcome variables analysedincluded number of follicles>12 mm in diameter, serum oestradiolconcentrations on the day of human chorionic gonadotrophin (HCG)administration, number of ampoules of HMG administered, numberof oocytes retrieved, percentage of oocytes fertilized, numberof embryos transferred, implantation rate and numbers of clinicalpregnancies and live birth pregnancies. The 31 randomized IVFcycles revealed a trend towards a higher implantation rate forthe placebo-treated group compared to the DEX-treated group(24 versus 10%P=0.07). The remainder of the IVF cycle variablesrevealed no statistically significant differences. In conclusion,the suppression of adrenal androgens with DEX in women withDHEAS concentrations >2.5 µg/ml appears to have nobeneficial effects on ovarian responsiveness or clinical orlive birth pregnancy rates. 相似文献
90.
Paul Peter Schneider Bram L. Ramaekers Xavier Pouwels Sandra Geurts Khava Ibragimova Maaike de Boer Birgit Vriens Yes van de Wouw Marien den Boer Manon Pepels Vivianne Tjan-Heijnen Manuela Joore 《Value in health》2021,24(5):668-675
ObjectivesPolicy makers increasingly seek to complement data from clinical trials with information from routine care. This study aims to provide a detailed account of the hospital resource use and associated costs of patients with advanced breast cancer in The Netherlands.MethodsData from 597 patients with advanced breast cancer, diagnosed between 2010 and 2014, were retrieved from the Southeast Netherlands Advanced Breast Cancer Registry. Database lock for this study was in October 2017. We report the observed hospital costs for different resource categories and the lifetime costs per patient, adjusted for censoring using Lin’s method. The relationship between patients’ characteristics and costs was studied using multivariable regression.ResultsThe average (SE) lifetime hospital costs of patients with advanced breast cancer were €52 709 (405). Costs differed considerably between patient subgroups, ranging from €29 803 for patients with a triple-negative subtype to €92 272 for patients with hormone receptor positive and human epidermal growth factor receptor 2 positive cancer. Apart from the cancer subtype, several other factors, including age and survival time, were independently associated with patient lifetime costs. Overall, a large share of costs was attributed to systemic therapies (56%), predominantly to a few expensive agents, such as trastuzumab (15%), everolimus (10%), and bevacizumab (9%), as well as to inpatient hospital days (20%).ConclusionsThis real-world study shows the high degree of variability in hospital resource use and associated costs in advanced breast cancer care. The presented resource use and costs data provide researchers and policy makers with key figures for economic evaluations and budget impact analyses. 相似文献